| [1] | Cashin A. G., Hansford H. J., Hernan M. A., et al. (2025). Transparent reporting of observational studies emulating a target trial-the TARGET statement. JAMA 334:1084−1093. DOI:10.1001/jama.2025.13350 |
| [2] | Cashin A. G., Hansford H. J., Hernan M. A., et al. (2025). Transparent reporting of observational studies emulating a target trial: The TARGET statement. BMJ 390:e087179. DOI:10.1136/bmj-2025-087179 |
| [3] | Hernán M. A. and Robins J. M. (2016). Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183:758−764. DOI:10.1093/aje/kwv254 |
| [4] | Franklin J. M., Glynn R. J., Suissa S., et al. (2020). Emulation differences vs. biases when calibrating real-world evidence findings against randomized controlled trials. Clin. Pharmacol. Ther. 107:735−737. DOI:10.1002/cpt.1793 |
| [5] | Wang S. V., Schneeweiss S., Initiative R.-D., et al. (2023). Emulation of randomized clinical trials with nonrandomized database analyses: Results of 32 clinical trials. JAMA 329:1376−1385. DOI:10.1001/jama.2023.4221 |
| Zhou J., Feng G. and Zhao Y. (2025). From emulation to evidence: The concepts, limitations, and prospects of TTE and TARGET. The Innovation Medicine 3:100172. https://doi.org/10.59717/j.xinn-med.2025.100172 |
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Development of Target Trial Emulation (TTE), including its concept, application, reporting, and evaluation.